Physician profile
Zehra Husain
NPI 1922276625
$3,441.22
in general payments reported to CMS, 2019-2025
27 companies · $536 in 2025
The $536 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $129 · 2021: $101 · 2022: $845 · 2023: $935 · 2024: $588 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,058.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $944.81 | 2019-2025 | Lifevest |
| Medtronic, INC. | $274.09 | 2022-2025 | Corevalve Evolut R |
| Astrazeneca Pharmaceuticals LP | $240.32 | 2019-2025 | Farxiga, Brilinta, Wainua |
| Novartis Pharmaceuticals Corporation | $216.00 | 2019-2025 | |
| Amgen INC. | $188.16 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.92 | 2019-2025 | Jardiance |
| Heartflow, INC. | $152.32 | 2023-2025 | Ffrct |
| Abbott Laboratories | $138.20 | 2019-2021 | |
| Esperion Therapeutics, INC. | $130.76 | 2022-2025 | Nexletol |
| Pfizer INC. | $127.75 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $119.64 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $95.57 | 2021-2023 | Verquvo |
| Alnylam Pharmaceuticals INC. | $82.75 | 2022-2023 | Onpattro |
| Kestra Medical Technology Services, INC. | $75.49 | 2023-2024 | Assure Wcd |
| Edwards Lifesciences Corporation | $57.81 | 2023 | Mitris Resilia Mitral Valve |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $54.59 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $52.24 | 2024 | Arcalyst |
| Novo Nordisk INC | $47.81 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $47.73 | 2022 | |
| Cordis US Corp. | $42.60 | 2025 | Mynx Control Venous |
| Irhythm Technologies, INC. | $40.20 | 2020-2021 | |
| Celgene Corporation | $32.40 | 2022-2023 | Camzyos |
| E.R. Squibb & Sons, L.L.C. | $32.24 | 2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $28.95 | 2020 | |
| Teleflex LLC | $17.40 | 2025 | Turnpike |
| Impulse Dynamics (USA) INC. | $13.95 | 2023 | Optimizer |
| Angiodynamics, INC. | $13.52 | 2024 | Auryon Laser System 100-120 Vac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zehra Husain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.